Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Anavex Life Sciences CorpAVXL-17.080.006.110.00-30.03%-30.19%78.53$8.96$0.0064,490$8.69

Detail of Anavex Life Sciences Corp

 
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Employees
40
Industry
Biotechnology
Sector
Healthcare
Market cap
$735M

Company details

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp
AVXL • XNGS • US
$8.69
+3.12 (56.05%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.51
Margin profit
0.00%
52 week low
$3.39
52 week high
$14.10
50-day simple moving average
$9.09
200-day simple moving average
$8.96
Percent held by insiders
3.05%
Percent held by institutions
32.04%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AVXL +49.10%
eps change
AVXL 0.00%